Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft

Molecular Cancer Therapeutics

Volumn 10, Issue 10, 2011, Pages 1949-1958

  Senra, Joana M ^a   Telfer, Brian A ^a   Cherry, Kim E ^b   McCrudden, Cian M ^b   Hirst, David G ^b   O'Connor, Mark J ^c   Wedge, Stephen R ^c   Stratford, Ian J ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; OLAPARIB; PHENYLEPHRINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL LINE; CYTOTOXICITY; DNA REPAIR; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY; RANDOMIZED CONTROLLED TRIAL; RAT; TISSUE PERFUSION; TUMOR REGRESSION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; VASODILATATION;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DNA REPAIR; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASES; RADIATION-SENSITIZING AGENTS; RATS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80053947757     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0278     Document Type: Article

References (46)

1. Chiarugi A. Poly(ADP-ribose) polymerase: killer or conspirator? The 'suicide hypothesis' revisited. Trends Pharmacol Sci 2002;23:122-9.
2. Gaal JC, Smith KR, Pearson CK. Cellular euthanasia mediated by a nuclear enzyme: a central role for nuclear ADP-ribosylation in cellular metabolism. Trends Biochem Sci1987;12:129-30. (Pubitemid 17049231)
3. Durkacz BW, Omidiji O, Gray DA, Shall S. (ADP-ribose)n participates in DNA excision repair. Nature 1980;283:593-6. (Pubitemid 10136042)
4. Borek C, Morgan WF, Ong A, Cleaver JE. Inhibition of malignant transformation in vitro by inhibitors of poly(ADP-ribose) synthesis. Proc Natl Acad Sci U S A 1984;81:243-7. (Pubitemid 14180865)
5. Thraves PJ, Mossman KL, Brennan T, Dritschilo A. Differential radiosensitization of human tumour cells by 3-aminobenzamide and benzamide: inhibitors of poly(ADP-ribosylation). Int J Radiat Biol Relat Stud Phys Chem Med 1986;50:961-72. (Pubitemid 17203021)
6. Brown DM, Evans JW, Brown JM. The influence of inhibitors of poly (ADP-ribose) polymerase on X-ray-induced potentially lethal damage repair. Br J Cancer Suppl 1984;6:27-31. (Pubitemid 14130889)
7. de Murcia JM, Niedergang C, Trucco C, Ricoul M, Dutrillaux B, Mark M, et al. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci U S A 1997;94:7303-7. (Pubitemid 27345310)
8. Molinete M, Vermeulen W, Burkle A, Menissier-de Murcia J, Kupper JH, Hoeijmakers JH, et al. Overproduction of the poly(ADP-ribose) polymerase DNA-binding domain blocks alkylation-induced DNA repair synthesis in mammalian cells. EMBO J 1993;12:2109-17. (Pubitemid 23157726)
9. Ben-Hur E, Utsumi H, Elkind MM. Inhibitors of poly (ADP-ribose) synthesis enhance radiation response by differentially affecting repair of potentially lethal versus sublethal damage. Br J Cancer Suppl 1984;6:39-42. (Pubitemid 14130891)
10. Ben-Hur E, Utsumi H, Elkind MM. Inhibitors of poly(ADP-ribose) synthesis enhance X-ray killing of log-phase Chinese hamster cells. Radiat Res 1984;97:546-55. (Pubitemid 14127981)
11. Masutani M, Nozaki T, Nakamoto K, Nakagama H, Suzuki H, Kusuoka O, et al. The response of Parp knockout mice against DNA damaging agents. Mutat Res 2000;462:159-66. (Pubitemid 30190223)
12. Watson CY, Whish WJ, Threadgill MD. Synthesis of 3-substituted benzamides and 5-substituted isoquinolin-1(2H)-ones and preliminary evaluation as inhibitors of poly(ADP-ribose)polymerase (PARP). Bioorg Med Chem 1998;6:721-34. (Pubitemid 28287274)
13. O'Connor MJ, Martin NM, Smith GC. Targeted cancer therapies based on the inhibition of DNA strand break repair. Oncogene 2007;26:7816-24. (Pubitemid 350242461)
14. Annunziata CM, O'Shaughnessy J. Poly (adp-ribose) polymerase as a novel therapeutic target in cancer. Clin Cancer Res 2010;16:4517-26.
15. Veuger SJ, Curtin NJ, Richardson CJ, Smith GC, Durkacz BW. Radio-sensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1. Cancer Res 2003;63:6008-15. (Pubitemid 37187504)
16. Liu SK, Coackley C, Krause M, Jalali F, Chan N, Bristow RG. A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia. Radiother Oncol 2008;88: 258-68.
17. Albert JM, Cao C, Kim KW, Willey CD, Geng L, Xiao D, et al. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res 2007;13:3033-42. (Pubitemid 46849580)
18. Dungey FA, Loser DA, Chalmers AJ. Replication-dependent radio-sensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential. Int J Radiat Oncol Biol Phys 2008;72:1188-97.
19. Calabrese CR, Almassy R, Barton S, Batey MA, Calvert AH, Canan- Koch S, et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 2004;96:56-67. (Pubitemid 38180960)
20. Donawho CK, Luo Y, Penning TD, Bauch JL, Bouska JJ, Bontcheva- Diaz VD, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 2007;13:2728-37. (Pubitemid 46795129)
21. Ali M, Telfer BA, McCrudden C, O'Rourke M, Thomas HD, Kamjoo M, et al. Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo? Clin Cancer Res 2009;15:6106-12.
22. Horsman MR, Brown JM, Hirst VK, Lemmon MJ, Wood PJ, Dunphy EP, et al. Mechanism of action of the selective tumor radiosensitizer nicotinamide. Int J Radiat Oncol Biol Phys 1988;15:685-90.
23. Horsman MR, Chaplin DJ, Brown JM. Tumor radiosensitization by nicotinamide: a result of improved perfusion and oxygenation. Radiat Res 1989;118:139-50. (Pubitemid 19112128)
24. Menear KA, Adcock C, Boulter R, Cockcroft XL, Copsey L, Cranston A, et al. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phth alazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem 2008;51:6581-91.
25. Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A 2008;105:17079-84.
26. Evers B, Drost R, Schut E, de Bruin M, van der Burg E, Derksen PW, et al. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res 2008;14:3916-25.
27. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-34.
28. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010;376:235-44.
29. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell- McGuinn KM, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010;376:245-51.
30. Loser DA, Shibata A, Shibata AK, Woodbine LJ, Jeggo PA, Chalmers AJ. Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair. Mol Cancer Ther 2010;9:1775-87.
31. Williams KJ, Telfer BA, Xenaki D, Sheridan MR, Desbaillets I, Peters HJ, et al. Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1. Radiother Oncol 2005;75: 89-98. (Pubitemid 40616800)
32. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer 2010;102:1555-77.
33. Williams KJ, Telfer BA, Shannon AM, Babur M, Stratford IJ, Wedge SR. Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: pathophysiologic effects and therapeutic benefit. Mol Cancer Ther 2007;6:599-606. (Pubitemid 46332462)
34. Russo AL, Kwon HC, Burgan WE, Carter D, Beam K, Weizheng X, et al. In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016. Clin Cancer Res 2009;15: 607-12.
35. Mah LJ, El-Osta A, Karagiannis TC. gammaH2AX: a sensitive molecular marker of DNA damage and repair. Leukemia 2010;24:679-86.
36. Ruddock MW, Hirst DG. Nicotinamide relaxes vascular smooth muscle by inhibiting myosin light chain kinase-dependent signaling pathways: implications for anticancer efficacy. Oncol Res 2004;14: 483-9. (Pubitemid 39551561)
37. Hirst DG, Kennovin GD, Flitney FW. The radiosensitizer nicotinamide inhibits arterial vasoconstriction. Br J Radiol 1994;67:795-9. (Pubitemid 24280131)
38. Hirst DG, Kennovin GD, Tozer GM, Prise VE, Flitney EW. The modification of blood flow in tumours and their supplying arteries by nicotinamide. Acta Oncol 1995;34:397-400.
39. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21. (Pubitemid 40559006)
40. Kaelin WG Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005;5:689-98.
41. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434:913-7. (Pubitemid 40559005)
42. Khan K, Araki K, Wang D, Li G, Li X, Zhang J, et al. Head and neck cancer radiosensitization by the novel poly(ADP-ribose) polymerase inhibitor GPI-15427. Head Neck 2010;32:381-91.
43. Williams KJ, Albertella MR, Fitzpatrick B, Loadman PM, Shnyder SD, Chinje EC, et al. In vivo activation of the hypoxia-targeted cytotoxin AQ4N in human tumor xenografts. Mol Cancer Ther 2009; 8:3266-75.
44. Kaanders JH, Bussink J, van der Kogel AJ. ARCON: a novel biology-based approach in radiotherapy. Lancet Oncol 2002;3:728-37. (Pubitemid 35446742)
45. Chaplin DJ, Horsman MR, Trotter MJ. Effect of nicotinamide on the microregional heterogeneity of oxygen delivery within a murine tumor. J Natl Cancer Inst 1990;82:672-6. (Pubitemid 20154274)
46. Kelleher DK, Vaupel PW. Nicotinamide exerts different acute effects on microcirculatory function and tissue oxygenation in rat tumors. Int J Radiat Oncol Biol Phys 1993;26:95-102. (Pubitemid 23137893)